CN117618338A - Stable orlistat medicine water solution and preparation method thereof - Google Patents
Stable orlistat medicine water solution and preparation method thereof Download PDFInfo
- Publication number
- CN117618338A CN117618338A CN202210981782.6A CN202210981782A CN117618338A CN 117618338 A CN117618338 A CN 117618338A CN 202210981782 A CN202210981782 A CN 202210981782A CN 117618338 A CN117618338 A CN 117618338A
- Authority
- CN
- China
- Prior art keywords
- streptococcus
- staphylococcus
- bacteroides
- haemophilus
- enterococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 14
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims description 15
- 229960001243 orlistat Drugs 0.000 title claims description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 29
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims abstract description 24
- 229960001607 oritavancin Drugs 0.000 claims abstract description 24
- 108010006945 oritavancin Proteins 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- GDFAOVXKHJXLEI-GSVOUGTGSA-N (2r)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C)C(O)=O GDFAOVXKHJXLEI-GSVOUGTGSA-N 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 238000002347 injection Methods 0.000 claims abstract description 11
- 241000589248 Legionella Species 0.000 claims description 19
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 19
- 241000918600 Corynebacterium ulcerans Species 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 241000606125 Bacteroides Species 0.000 claims description 11
- 241000194033 Enterococcus Species 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 241000606768 Haemophilus influenzae Species 0.000 claims description 7
- 241000191967 Staphylococcus aureus Species 0.000 claims description 7
- 108010059993 Vancomycin Proteins 0.000 claims description 7
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 7
- 229960003165 vancomycin Drugs 0.000 claims description 7
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 7
- 241000588768 Providencia Species 0.000 claims description 6
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims description 6
- 241000588779 Bordetella bronchiseptica Species 0.000 claims description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 5
- 241000191940 Staphylococcus Species 0.000 claims description 5
- 241000194046 Streptococcus intermedius Species 0.000 claims description 5
- 241000607479 Yersinia pestis Species 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 4
- 241000588624 Acinetobacter calcoaceticus Species 0.000 claims description 4
- 241001148231 Acinetobacter haemolyticus Species 0.000 claims description 4
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims description 4
- 241000588780 Bordetella parapertussis Species 0.000 claims description 4
- 241000588832 Bordetella pertussis Species 0.000 claims description 4
- 241000589513 Burkholderia cepacia Species 0.000 claims description 4
- 241000588919 Citrobacter freundii Species 0.000 claims description 4
- 241000193163 Clostridioides difficile Species 0.000 claims description 4
- 241000186227 Corynebacterium diphtheriae Species 0.000 claims description 4
- 241001600125 Delftia acidovorans Species 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 241000588697 Enterobacter cloacae Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000606788 Haemophilus haemolyticus Species 0.000 claims description 4
- 241000606822 Haemophilus parahaemolyticus Species 0.000 claims description 4
- 241000606766 Haemophilus parainfluenzae Species 0.000 claims description 4
- 241000590002 Helicobacter pylori Species 0.000 claims description 4
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 4
- 241000588772 Morganella morganii Species 0.000 claims description 4
- 241000186367 Mycobacterium avium Species 0.000 claims description 4
- 241000186364 Mycobacterium intracellulare Species 0.000 claims description 4
- 241000186362 Mycobacterium leprae Species 0.000 claims description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 4
- 241000588770 Proteus mirabilis Species 0.000 claims description 4
- 241000588767 Proteus vulgaris Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 241000168225 Pseudomonas alcaligenes Species 0.000 claims description 4
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 4
- 241000589776 Pseudomonas putida Species 0.000 claims description 4
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 claims description 4
- 241000607715 Serratia marcescens Species 0.000 claims description 4
- 241000607764 Shigella dysenteriae Species 0.000 claims description 4
- 241000607762 Shigella flexneri Species 0.000 claims description 4
- 241000607760 Shigella sonnei Species 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 4
- 241000192087 Staphylococcus hominis Species 0.000 claims description 4
- 241001464905 Staphylococcus saccharolyticus Species 0.000 claims description 4
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims description 4
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 4
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 4
- 241000607477 Yersinia pseudotuberculosis Species 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 4
- 229940037467 helicobacter pylori Drugs 0.000 claims description 4
- 229940076266 morganella morganii Drugs 0.000 claims description 4
- 229940007042 proteus vulgaris Drugs 0.000 claims description 4
- 229940007046 shigella dysenteriae Drugs 0.000 claims description 4
- 229940115939 shigella sonnei Drugs 0.000 claims description 4
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 4
- 241000589877 Campylobacter coli Species 0.000 claims description 3
- 241000589874 Campylobacter fetus Species 0.000 claims description 3
- 241000589875 Campylobacter jejuni Species 0.000 claims description 3
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- 241000606790 Haemophilus Species 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 241001293418 Mannheimia haemolytica Species 0.000 claims description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229940055033 proteus mirabilis Drugs 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 241001135322 Bacteroides eggerthii Species 0.000 claims description 2
- 241000606219 Bacteroides uniformis Species 0.000 claims description 2
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 2
- 241000589602 Francisella tularensis Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000588749 Klebsiella oxytoca Species 0.000 claims description 2
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 2
- 241001135232 Odoribacter splanchnicus Species 0.000 claims description 2
- 241000606856 Pasteurella multocida Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 241000588777 Providencia rettgeri Species 0.000 claims description 2
- 241000588778 Providencia stuartii Species 0.000 claims description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 2
- 241000191980 Staphylococcus intermedius Species 0.000 claims description 2
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607481 Yersinia intermedia Species 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 229940118764 francisella tularensis Drugs 0.000 claims description 2
- 229940051027 pasteurella multocida Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 2
- 239000003186 pharmaceutical solution Substances 0.000 claims 10
- 241000194017 Streptococcus Species 0.000 claims 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 3
- 241000589291 Acinetobacter Species 0.000 claims 1
- 241001135228 Bacteroides ovatus Species 0.000 claims 1
- 241000606215 Bacteroides vulgatus Species 0.000 claims 1
- 241000588807 Bordetella Species 0.000 claims 1
- 241000589968 Borrelia Species 0.000 claims 1
- 241000589876 Campylobacter Species 0.000 claims 1
- 241000606807 Glaesserella parasuis Species 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000588621 Moraxella Species 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 241001291896 Streptococcus constellatus Species 0.000 claims 1
- 241000187747 Streptomyces Species 0.000 claims 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 abstract description 11
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract description 11
- 229960005017 olanzapine Drugs 0.000 abstract description 11
- 239000003381 stabilizer Substances 0.000 abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- -1 4’-chloro[1,1’-biphenyl]-4-yl Chemical group 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 2
- RNMCCPMYXUKHAZ-UHFFFAOYSA-N 2-[3,3-diamino-1,2,2-tris(carboxymethyl)cyclohexyl]acetic acid Chemical compound NC1(N)CCCC(CC(O)=O)(CC(O)=O)C1(CC(O)=O)CC(O)=O RNMCCPMYXUKHAZ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000036647 Medication errors Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- MAEBCGDGGATMSC-OSHGGGOQSA-N cyclamine Chemical compound O([C@H]1CO[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CCC45OCC6([C@@H](C[C@@]4(C)[C@]3(C)CCC2C1(C)C)O)CC[C@@](C[C@@H]65)(C)C=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O MAEBCGDGGATMSC-OSHGGGOQSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 description 2
- UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 2
- QXOCYGPVDXDFLC-UHFFFAOYSA-N n-ethyl-n'-[4-[4-(ethylamino)butylamino]butyl]butane-1,4-diamine Chemical compound CCNCCCCNCCCCNCCCCNCC QXOCYGPVDXDFLC-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical class NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- YDVODBIDDSGKAD-UHFFFAOYSA-N 1,4,7,11-tetrazacyclotetradecane Chemical compound C1CNCCCNCCNCCNC1 YDVODBIDDSGKAD-UHFFFAOYSA-N 0.000 description 1
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 208000012503 Bathing suit ichthyosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000235172 Bullera Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical class CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 241000576783 Providencia alcalifaciens Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical group CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- AWGTVRDHKJQFAX-UHFFFAOYSA-M chloro(phenyl)mercury Chemical compound Cl[Hg]C1=CC=CC=C1 AWGTVRDHKJQFAX-UHFFFAOYSA-M 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a stable aqueous solution of an olanzapine drug and a preparation method thereof, wherein the aqueous solution of the olanzapine comprises the following components: orlivancin or pharmaceutically acceptable salt thereof, N-methyl-D-alanine, and water. The aqueous solution of the oritavancin drug provided by the invention takes N-methyl-D-alanine as a stabilizer, greatly reduces the growth rate of impurities in the aqueous solution at 25 ℃, and the impurity change is less than 0.1% after 30 days; high safety and high stability, and the maximum impurity content is less than 0.1% even if the product is stored at normal temperature. It is a stable ready-to-use injection.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a stable aqueous solution of an olanzapine drug and a preparation method thereof.
Background
Oritavancin (Oritavancin) chemical name is: [4"R ]]-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-Larabino-hexopyranosyl)-N3-[(4’-chloro[1,1’-biphenyl]-4-yl)methyl]vancomycin phosphate[1:2][salt]The molecular formula is: c (C) 86 H 97 N 10 O 26 C l3 ·2H 3 PO 4 The molecular weight is: 1989.09 its phosphate form has the structural formula:
oritavancin (Oritavancin) is a novel semisynthetic lipopeptide antibiotic. Oriwaxs have been shown to be effective in treating adult patients 18 years and older suffering from acute bacterial skin infections and skin structure infections (ABSSSI) caused or suspected to be caused by sensitive isolates of designated gram positive microorganisms. The current preparation of oritavancin is a freeze-dried powder injection, and requires at least one dilution before use, is inconvenient for clinical use and is prone to errors.
CN 106620649A discloses that oritavancin shows significant activity against many bacteria. This application text describes methods of treating, preventing and preventing bacterial infections and diseases in animals, including humans, using single doses of oritavancin during a course of treatment.
CN108712909a discloses a lyophilized powder formulation comprising orivancin and a beta-cyclodextrin derivative.
CN105641679a provides a stable orlistat pharmaceutical composition: oridancin, mannitol, phosphoric acid and water for injection. But is preferably in the form of a lyophilized powder for injection.
The orlistat is only marketed as freeze-dried powder injection and used for intravenous injection in abroad. The oridanin freeze-dried powder injection shows rapid degradation during reconstitution, and the oridanin aqueous solution also shows degradation during short storage, so the oridanin is not suitable for long-term storage in the aqueous solution. Therefore, a Ready-To-Use injection (RTU) is continuously developed, and compared with a freeze-dried powder injection, the RTU can be directly used clinically without a re-dissolution step, and the medication error is reduced.
Disclosure of Invention
In order to solve the problems in the prior art, the invention adopts N-methyl-D-alanine as a stabilizer, can reduce the degradation rate of the orlistat in the aqueous solution, and prepares the stable aqueous solution preparation of the orlistat. The invention provides a stable aqueous solution of an olanzapine drug, comprising the following components: orlivancin or pharmaceutically acceptable salt thereof, N-methyl-D-alanine, and water.
The pharmaceutically acceptable salts are, for example, acid salts and/or base salts, which salts may be formed with inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Inorganic acids from which salts may be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts may be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. The base salts may be formed as pharmaceutically acceptable salts using inorganic and organic bases. Inorganic bases from which salts may be derived include, for example, bases containing sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are ammonium, potassium, sodium, calcium and magnesium salts. In some embodiments, treatment of the orivancin with an inorganic base loses labile hydrogen from the orivancin to provide a solution comprising inorganic cations (such as li+, na+, k+, mg) 2+ And Ca 2+ Etc.). Organic bases from which salts may be derived include, for example, primary, secondary and tertiary amines, substituted amines, cyclic amines, basic ion exchange resins, and the like, such as, inter alia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine and ethanolamine.
Wherein the content of said oritavancin or pharmaceutically acceptable salt thereof is 0.1-30% w/w, preferably 0.1-25% w/w, preferably 0.1-20% w/w, preferably 0.1-15% w/w, preferably 0.1-10% w/w, further preferably 0.1-5% w/w.
Wherein the N-methyl-D-alanine content is 0.1-60% w/w, preferably 0.5-60% w/w, further preferably 1-60% w/w.
Furthermore, an organic solvent can be added into the aqueous solution of the orivancin drug, and the organic solvent can be commonly used in liquid preparations, such as ethanol, glycerol, propylene glycol, dimethyl sulfoxide and polyethylene glycol.
The aqueous solution formulation of the oritavancin preferably has a pH of 3 to 8, more preferably 4 to 7. In particular embodiments, the pH of the final aqueous preparation of oritavancin is about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, or about 8; preferably about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7.
The aqueous solution of the oritavancin drug can further comprise one or a combination of more than two of solubilizer, surfactant, buffer, antioxidant, preservative and chelating agent.
The solubilizer is selected from ionic surfactant or nonionic surfactant, such as sodium dodecyl sulfate, tween 80, span 20, etc., and the dosage thereof is usually 0.01-20.0 g/100mL. The solubilizers are described herein by way of example only and are not intended to limit the scope of the present invention. Any suitable solubilizing agent known to those skilled in the art is suitable for use in the present invention.
Various buffers and methods may be used for adjusting the pH, including acetate buffers, citrate buffers, phosphate buffers, tartrate buffers, amino acid salts, and borate buffers. Acids or bases may be used to adjust the pH of these formulations as desired.
Such antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, and butylated hydroxytoluene. The amount is usually 0.001 to 5.0g/100mL.
The preservative includes, but is not limited to, one or more of benzalkonium chloride, polyhexamethylene chloride (PHMB), chlorobutanol, thimerosal, phenylmercuric chloride, acetate, phenylmercuric nitrate, ethylparaben, parabens, benzoic acid and salts thereof, sorbic acid, chlorobutanol, benzyl alcohol, phenethyl alcohol, chlorhexidine acetate, and quaternary ammonium compound cationic surfactants, typically in an amount of 0.005 to 10.0g/100mL. The preservative is described herein by way of example only and is not intended to limit the scope of the invention. Any suitable preservative known to those skilled in the art is suitable for use in the present invention.
The chelating agents include various dicarboxylic, tricarboxylic and aminopolycarboxylic acids, such as ethylenediamine tetraacetic acid (EDTA), ethylene glycol-bis (β -aminoethyl ether) -N, N' -tetraacetic acid (EGTA) and penta (carboxymethyl) Diethylenetriamine (DTPA), and salts and hydrates thereof; monomeric polyacids such as EDTA, cyclohexanediamine tetraacetic acid (CDTA), hydroxyethylethylenediamine triacetic acid (HEDTA), diethylenetriamine pentaacetic acid (DTPA), dimercaptopropane sulfonic acid (DMPS), dimercaptosuccinic acid (DMSA), aminotrimethylene phosphonic acid (ATPA), citric acid, ophthalmically acceptable salts thereof, and combinations of any of the foregoing may also be included. Other suitable chelators include pyrophosphates, triphosphates and hexametaphosphate, chelated antibiotics such as chloroquine and tetracyclines, nitrogen-containing chelators containing two or more chelated nitrogen atoms within the imino group or in the aromatic ring (e.g., diimine, 2' -bipyridine, etc.), and various polyamines such as cyclamine (Cyclam) (1,4,7,11-tetraazacyclotetradecane), N- (C1 to C30 alkyl) -substituted cyclamine (e.g., hexadecyl cyclamine, tetramethyl hexadecyl cyclamine), diethylenetriamine (DETA), spermine, diethyl norspermine (DENSPM), diethyl homospermine (DEHOP), and deferoxamine (N ' - [5- [ [5- (acetylhydroxyamino) pentyl ] amino ] -1, 4-dioxobutyl ] hydroxy-amino ] pentyl ] -N ' - (5-aminopentyl) -N-hydroxybutyl diamide, typically in amounts of 0.01 to 5.0g/100mL.
In another aspect of the invention, a preparation method of an olanzapine medicine aqueous solution is provided, wherein the preparation method comprises the steps of weighing N-methyl-D-alanine with a prescription dose, adding the N-methyl-D-alanine into water, stirring to dissolve, weighing the oritavancin with the prescription dose, and stirring to dissolve to obtain the oritavancin medicine aqueous solution.
In the presence of other excipients, further comprising the step of adding other excipients including, but not limited to, the solubilizing agents, surfactants, buffers, antioxidants, preservatives, chelating agents and combinations of any two or more thereof.
The aqueous solution of the oridanin disclosed herein can be oral liquid, injection, eye drops, external gel, external emulsion and spray.
Administration of the formulations prepared from the aqueous solutions of the oritavancin drug disclosed herein may be via any acceptable mode of administration for agents having similar uses, including, but not limited to, oral, subcutaneous, intravenous, intranasal, topical, transdermal, intraperitoneal, intramuscular, intrapulmonary, vaginal, rectal, or intraocular administration.
The invention also provides application of the oritavancin drug aqueous solution in preparation of drugs for treating bacterial infection. The infection may be in any tissue or tissue of the subject. For example, the aqueous solution of olanzapine provided by the present invention may be used to treat a subject suffering from: blood flow infections (BSIs), catheter related blood flow infections (CRBSIs), osteomyelitis, prosthetic joint infections, pneumonia, joint space infections, and device infections.
The aqueous solution of the oritavancin drug provided by the invention can be used for treating a subject suffering from the following infection: complex skin infections and skin structure infections (cSSSI) and complex and uncomplicated skin infections and soft tissue infections (SSTI), including abscesses, ulcers, burns, cellulitis, deep bacterial infections (such as severe abscesses, infectious ulcers, severe burns, or deep and extensive cellulitis). The treatment methods may also be carried out with surgery for bacterial infection.
In some specific embodiments, the subject may be an animal, e.g., a mammal, a human.
Examples of bacterial infections include Pseudomonas aeruginosa (Pseudomonas aeruginosa), pseudomonas fluorescens (Pseudomonas fluorescens), pseudomonas acidovorans (Pseudomonas acidovorans), pseudomonas alcaligenes (Pseudomonas alcaligenes), pseudomonas putida (Pseudomonas putida), pseudomonas maltophilia (Stenotrophomonas maltophilia), burkholderia cepacia (Burkholderia cepacia), aeromonas hydrophila (Aeromonas hydrophilia), escherichia coli (Escherichia coli), citrobacter freundii (Citrobacter freundii), salmonella typhimurium (Salmonella typhimurium), salmonella typhimurium (Salmonella typhi), salmonella paratyphi (Salmonella paratyphi), salmonella enteritidis, shigella dysenteriae (Shigella dysenteriae), shigella flexneri (Shigella flexneri) Shigella sonnei (Shigella sonnei), enterobacter cloacae (Enterobacter cloacae), enterobacter aerogenes (Enterobacter aerogenes), klebsiella pneumoniae (Klebsiella pneumoniae), klebsiella oxytoca (Klebsiella oxytoc), serratia marcescens (Serratia marcescens), franciscensis (Francisella tularensis), morganella morganii (Morganella morganii), proteusmirabilis (Proteusmirabilis), proteus vulgaris (Proteus vulgaris), providencia alcalifaciens (providens), providencia rex (Providencia rettgeri), providencia sii (Providencia stuartii), acinetobacter baumannii (Acinetobacter baumannii), acinetobacter calcoaceticus (Acinetobacter calcoaceticus), acinetobacter haemolyticus (Acinetobacter haemolyticus), yersinia enterocolitica (Yersinia enterocolitica), yersinia pestis (Yersinia pestis), yersinia pseudotuberculosis (Yersinia pseudotuberculosis), yersinia intermedia (Yersinia), bordetella pertussis (Bordetella pertussis), bordetella parapertussis (Bordetella parapertussis), bordetella bronchiseptica (Bordetella bronchiseptica), haemophilus influenzae (Haemophilus influenzae), haemophilus parainfluenza (Haemophilus parainfluenzae), haemophilus haemolyticus (Haemophilus haemolyticus), haemophilus parahaemolyticus (Pasteurella multocida), basidiomycetes haemophilus dukoti (Pasteurella haemolytica), bullera catarrhalis (Branhamella catarrhalis), helicobacter pylori (Helicobacter pylori), campylobacter fetus (Campylobacter fetus), campylobacter jejuni (Campylobacter jejuni), campylobacter coli (4846), bolborospirochete (Borrelia burgdorferi), haemophilus cholerae (Vibrio), haemophilus parahaemolyticus (Haemophilus influenzae), legionella spp (35A), legionella spp (35) and Metropellae (35A), legionella spp (35) are provided by the genus Legionella (35A), legionella (35) and the genus Legionella (35A) are provided by the genus Legionella (35) and the genus Legionella (35) including the genus Legionella (35A), the genus Legionella (35) and the genus Legionella (35), bacteroides vulnificus (Bacteroides ovalus), bacteroides thetaiotaomicron (Bacteroides thetaiotaomicron), bacteroides simplex (Bacteroides uniformis), bacteroides elmendocina (Bacteroides eggerthii), bacteroides visceral (Bacteroides splanchnicus), clostridium difficile (Clostridium difficile), mycobacterium tuberculosis (Mycobacterium tuberculosis), mycobacterium avium (Mycobacterium avium), mycobacterium intracellulare (Mycobacterium intracellulare), mycobacterium leprae (Mycobacterium leprae), corynebacterium diphtheriae (Corynebacterium diphtheriae), corynebacterium ulcerans (Corynebacterium ulcerans), streptococcus pneumoniae (Corynebacterium ulcerans), streptococcus agalactiae (Corynebacterium ulcerans), streptococcus pyogenes (Corynebacterium ulcerans), streptococcus intermedius (Corynebacterium ulcerans), streptococcus dysgalactiae (Corynebacterium ulcerans), enterococcus faecalis (Corynebacterium ulcerans), enterococcus faecium (enterococcus), enterococcus (vancomycin-Corynebacterium ulcerans), enterococcus (Corynebacterium ulcerans), staphylococcus aureus (Corynebacterium ulcerans), and vancomycin-37, and vancomycin-resistant Staphylococcus (Corynebacterium ulcerans), vancomycin heterogeneously moderately resistant Staphylococcus aureus (vancomycin hetero-intermediate Staphylococcus aureus), staphylococcus epidermidis (Staphylococcus epidermidis), staphylococcus saprophyticus (Staphylococcus saprophyticus), staphylococcus intermedia (Staphylococcus intermedius), staphylococcus hyicussubsp. Hyicus, staphylococcus hemolyticus (Staphylococcus haemolyticus), staphylococcus hominis (Staphylococcus hominis), or Staphylococcus saccharolyticus (Staphylococcus saccharolyticus), and combinations thereof.
The bacterial infection treated by the aqueous solution of olanzapine provided by the present invention may be caused by any of the phenotypes or genotypes of bacteria provided above, or by any other bacteria described above that are capable of causing a bacterial infection. In the present invention, the infection being treated may be caused by more than one bacterial species, or by more than one phenotype or genotype of a single bacterial species. For example, the infection treated may be a complex skin infection and a skin structure infection.
The invention obtains the aqueous solution of the olanzapine medicine on the basis of a large number of experiments, takes N-methyl-D-alanine as a stabilizer, and has the following beneficial effects: the method provided by the invention has the advantages that the growth speed of impurities in the aqueous solution is greatly reduced under the condition of 25 ℃, and the impurity change is less than 0.1% after 30 days; high safety and high stability, and the maximum impurity content is less than 0.1% even if the product is stored at normal temperature. The injection is a Ready-To-Use (RTU) with good stability, and compared with a freeze-dried powder injection, the RTU can be directly used clinically without a re-dissolution step, and the medication error is reduced.
Drawings
FIG. 1 is a 25-60 day HPLC chart of prescription 17.
FIG. 2 is a 25-60 day HPLC chart of prescription 16.
FIG. 3 is a 25-60 day HPLC chart of prescription 15.
Detailed Description
The invention will be further described in connection with specific embodiments, but the invention is not limited thereto.
The HPLC method used for detecting the stability of the olanzapine comprises the following steps:
solution a: precisely measuring 4.0ml of triethylamine, adding water to 2000ml, and regulating the pH to 3.20 by phosphoric acid;
solution B: acetonitrile-tetrahydrofuran-solution a=55-10-935, phosphoric acid adjusted pH to 3.20;
solution C: acetonitrile-tetrahydrofuran-solution a=290-10-700, phosphoric acid adjusted to pH 3.20;
elution gradient:
Time | Solution B(%) | Solution C(%) |
0 | 100 | 0 |
12 | 100 | 0 |
20 | 0 | 100 |
23 | 100 | 0 |
32 | 100 | 0 |
example 1: stability of formulations of oritavancin and different amino acids and derivatives thereof
The preparation method comprises the following steps:
1. weighing amino acid or its derivative in a prescribed amount in a beaker, adding water in the prescribed amount, and stirring to dissolve;
2. weighing the formula amount of the orlistat, and stirring for dissolution;
3. after a certain time at 25℃the sample was taken and tested, the percentage relative to the initial was calculated and the results were as follows.
Total impurities | Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 | Prescription 6 | Prescription 7 |
Day 0 | 98.3% | 98.2% | 98.5% | 98.0% | 99.0% | 98.3% | 98.9% |
For 30 days | 90.1% | 92.3% | 89.3% | 84.0% | 97.6% | 94.4% | 95.9% |
As can be seen from the above results, the addition of the amino acid or derivative thereof reduces the degradation of the Orliwan star in aqueous solution, reduces the increase of total impurities, and increases its stability, wherein N-methyl-D-alanine is most effective, with a relative purity of 98.6, which is the ratio of the purity after a period of time to the initial purity, for example, the relative purity of formula 5 is 97.6%/99.0%.
Example 2: stability of olanzapine and different organic solvent formulations
The preparation method comprises the following steps:
1. weighing a prescribed amount of organic solvent in a beaker, adding the organic solvent into 50ml of water for injection, and stirring to dissolve the organic solvent;
2. weighing the formula amount of the orlistat, and stirring for dissolution;
3. after a certain time at 25℃the sample was taken and tested, the percentage relative to the initial was calculated and the results were as follows.
The above results show that the crystal precipitation of the orlistat is achieved by adding a small amount of N, N dimethylacetamide, polyethylene glycol 400, propylene glycol and ethanol into the formula of the orlistat aqueous solution, which indicates that the physical compatibility of the orlistat with the above organic solvents is poor. In lower concentrations of glycerol, flocculent precipitate did not appear, but there was limited inhibition of degradation of the olympic cycle.
Experimental example 3: effect of different concentrations of stabilizers on stability of the oritavancin prescription
The preparation method comprises the following steps:
1. weighing a prescribed amount of organic solvent in a beaker, adding the organic solvent into 50ml of water for injection, and stirring to dissolve the organic solvent;
2. weighing the formula amount of the orlistat, and stirring for dissolution;
3. after being placed at 25 ℃ for a certain period of time, the sample is taken and detected, and the peak area percentage is calculated according to area normalization, and the result is as follows.
Total impurities | Prescription 14 | Prescription 15 | Prescription 16 | Prescription 17 |
Day 0 | 98.0% | 98.5% | 98.9% | 99.1% |
For 30 days | 97.8% | 98.2% | 98.5% | 99.6% |
For 60 days | 97.9% | 98.1% | 98.5% | 99.0% |
The above results show that formulations 14-17 are less degraded within 60 days and remain stable for a longer period of time than formulation 1, an aqueous solution of olympic vancin, in the presence of stabilizer N-methyl-D-alanine at different ratios. FIG. 1 is a prescription 17, 25-60 day HPLC profile, integration data as follows:
fig. 2 is a prescription 16, 25-60 day HPLC profile, integration data as follows:
fig. 3 is a prescription 15, 25-60 day HPLC profile, integration data as follows:
example 4: stability of formulations of different concentrations of oritavancin and N-methyl-D-alanine
The preparation method comprises the following steps:
1. weighing N-methyl-D-alanine with a prescription amount in a beaker, adding water with the prescription amount, and stirring to dissolve;
2. weighing the formula amount of the orlistat, and stirring for dissolution;
3. after a certain time at 25℃the sample was taken and tested, the percentage relative to the initial was calculated and the results were as follows.
Total impurities | Prescription 18 | Prescription 19 | Prescription 20 | Location 21 | Prescription 22 | Prescription 23 |
Day 0 | 99.1% | 98.9% | 98.7% | 98.2% | 98.6% | 98.6% |
For 30 days | 98.8% | 98.1% | 98.0% | 97.9% | 97.5% | 96.5% |
The above results show that the addition of N-methyl-D-alanine can reduce the degradation of the oritavancin with different concentrations in the aqueous solution, reduce the increase of total impurities and increase the stability of the oritavancin.
Example 5: stability of the formulations with different organic solvents after addition of stabilizers to olanzapine
The preparation method comprises the following steps:
1. weighing a prescribed amount of organic solvent and N-methyl-D-alanine or N-acetyl-D-alanine in a beaker, adding the mixture into 50ml of water for injection, and stirring the mixture to dissolve the mixture;
2. weighing the formula amount of the orlistat, and stirring for dissolution;
3. after a certain time at 25℃the sample was taken and tested, the percentage relative to the initial was calculated and the results were as follows.
The above results show that, in the formula of the aqueous solution of the olympic games, a small amount of N, N dimethylacetamide, polyethylene glycol 400, propylene glycol and ethanol are added, the olympic games are crystallized out originally, but the improvement effect is obvious after the stabilizer is added, but the improvement effect of N-acetyl-D-alanine is not obvious, the improvement effect of N-methyl-D-alanine is obvious, and the degradation of the olympic games can be inhibited.
Claims (11)
1. A stable aqueous solution of an orlistat drug comprising the components: orlivancin or pharmaceutically acceptable salt thereof, N-methyl-D-alanine, and water.
2. The aqueous pharmaceutical solution of claim 1, wherein the pharmaceutically acceptable salt is a hydrochloride or base salt.
3. The aqueous pharmaceutical solution according to claim 1, wherein the content of the olympic games or pharmaceutically acceptable salts thereof is 0.1-30% w/w, preferably 0.1-25% w/w, preferably 0.1-20% w/w, preferably 0.1-15% w/w, preferably 0.1-10% w/w, further preferably 0.1-5% w/w.
4. The aqueous pharmaceutical solution according to claim 1, wherein the N-methyl-D-alanine content is 0.1-60% w/w, preferably 0.5-60% w/w, further preferably 1-60% w/w.
5. The aqueous pharmaceutical solution of claim 1, further comprising an organic solvent selected from, but not limited to, ethanol, glycerol, propylene glycol, dimethyl sulfoxide, polyethylene glycol.
6. The aqueous pharmaceutical solution according to claims 1-5, having a pH of 3-8.
7. The aqueous pharmaceutical solution of claim 6, further comprising one or a combination of any two or more of a solubilizer, a surfactant, a buffer, an antioxidant, a preservative, and a chelating agent.
8. The method for preparing an aqueous pharmaceutical solution according to any one of claims 1 to 7, wherein the prescribed amount of N-methyl-D-alanine or other auxiliary materials (if present) is weighed, added into water and stirred to dissolve, then the prescribed amount of oritavancin is weighed, and the oritavancin aqueous pharmaceutical solution is obtained by stirring and dissolving.
9. Use of the aqueous pharmaceutical solution according to any one of claims 1-7 for the preparation of oral liquids, injections, eye drops, topical gels, topical emulsions, sprays.
10. Use of an aqueous pharmaceutical solution according to any one of claims 1-7 and 9 for the preparation of a medicament for the treatment of a bacterial infection.
11. The use according to claim 10, wherein the bacterial infection comprises Pseudomonas aeruginosa (Pseudomonas aeruginosa), pseudomonas fluorescens (Pseudomonas fluorescens), pseudomonas acidovorans (Pseudomonas acidovorans), pseudomonas alcaligenes (Pseudomonas alcaligenes), pseudomonas putida (Pseudomonas putida), pseudomonas maltophilia (Stenotrophomonas maltophilia), burkholderia cepacia (Burkholderia cepacia), aeromonas hydrophila (Aeromonas hydrophilia), escherichia coli (Escherichia coli), citrobacter freundii (Citrobacter freundii), salmonella typhimurium (Salmonella typhimurium), salmonella typhi (Salmonella typhi), salmonella paratyphi (Salmonella paratyphi), salmonella enteritidis, shigella dysenteriae (Shigella dysenteriae), shigella flexneri (Shigella flexneri) Shigella sonnei (Shigella sonnei), enterobacter cloacae (Enterobacter cloacae), enterobacter aerogenes (Enterobacter aerogenes), klebsiella pneumoniae (Klebsiella pneumoniae), klebsiella oxytoca (Klebsiella oxytoc), serratia marcescens (Serratia marcescens), franciscensis tularensis (Francisella tularensis), morganella morganii (Morganella morganii), proteusmirabilis (Proteus mirabilis), proteus vulgaris (Proteus vulgaris), providencia alcalifasens (providencia), providencia rex (Providencia rettgeri), providencia sii (Providencia stuartii), acinetobacter baumannii (Acinetobacter baumannii), acinetobacter calcoaceticus (Acinetobacter calcoaceticus), acinetobacter (Acinetobacter haemolyticus) haemolyticus (Acinetobacter haemolyticus), yersinia enterocolitica (Yersinia enterocolitica), yersinia pestis (Yersinia pestis), yersinia pseudotuberculosis (Yersinia pseudotuberculosis), yersinia intermedia (Yersinia pestis), bordetella pertussis (Bordetella pertussis), bordetella parapertussis (Bordetella parapertussis), bordetella bronchiseptica (Bordetella bronchiseptica), haemophilus influenzae (Haemophilus influenzae), haemophilus parainfluenzae (Haemophilus parainfluenzae), haemophilus haemolyticus (Haemophilus haemolyticus), haemophilus parahaemolyticus (haemal haemophilus parasuis) (Haemophilus ducreyi), pasteuresis (Pasteurella multocida), pasteurella haemolytica (Pasteurella haemolytica), bulborococcus mucositis (Branhamella catarrhalis), helicobacter pylori (Helicobacter pylori), campylobacter feti (Campylobacter fetus), campylobacter jejuni (673), campylobacter coli (Campylobacter coli), borrelia bordetella (Borrelia burgdorferi), haemophilus cholerae (Bordetella bronchiseptica), haemophilus influenzae (Haemophilus influenzae), haemophilus parahaemolyticus (Neisseria meningitidis), vibrio vulus (35, moraxella (35) and morbus (Levalacia) are described in the genus Leideae (Leideae), legionella (35) and the genus Legionella (Legionella) such as Legionella (Legionella), legionella (35) and the genus Legionella (Legionella), the Bacteroides 3452A homolog group (Bactoides 3452A homolog group), bacteroides vulgaris (Bacteroides vulgatus), bacteroides ovatus (Bacteroides ovalus), bacteroides thetaiotaomicron (Bacteroides thetaiotaomicron), bacteroides simplex (Bacteroides uniformis), bacteroides (Bacteroides eggerthii), bacteroides viscus (Bacteroides splanchnicus), clostridium difficile (Clostridium difficile), mycobacterium tuberculosis (Mycobacterium tuberculosis), mycobacterium avium (Mycobacterium avium), mycobacterium intracellulare (Mycobacterium intracellulare), mycobacterium leprae (Mycobacterium leprae), corynebacterium diphtheriae (Corynebacterium diphtheriae), corynebacterium ulcerans (Corynebacterium ulcerans), streptococcus pneumoniae (Streptococcus pneumoniae), streptococcus agalactis (Streptococcus agalactiae), streptococcus pyogenes (Streptococcus pyogenes), streptococcus intermedius (Streptococcus intermedius), streptococcus intermedius (Streptococcus intermedius), streptococcus constellation (Streptococcus constellatus), streptococcus dysgalactiae (Streptococcus dysgalactiae), streptococcus dysenteriae (Streptomyces dysenteriae), enterococcus (Streptococcus dysgalactiae), enterococcus (enterococcus faecium faecalis), enterococcus (enterococcus) bacteria (Streptococcus dysgalactiae), enterococcus (enterococcus faecium), enterococcus (Streptococcus dysgalactiae), and enterococcus (37) vancomamoxico (37) and enterococcus (37-37), vancomycin moderately tolerating Staphylococcus aureus (vancomycin-intermediate Staphylococcus aureus), vancomycin heterogeneously moderately tolerating Staphylococcus aureus (vancomycin hetero-intermediate Staphylococcus aureus), staphylococcus epidermidis (Staphylococcus epidermidis), staphylococcus saprophyticus (Staphylococcus saprophyticus), staphylococcus intermedia (Staphylococcus intermedius), staphylococcus suis subsp. Hyicus, staphylococcus hemolyticus (Staphylococcus haemolyticus), staphylococcus hominis (Staphylococcus hominis), or Staphylococcus saccharolyticus (Staphylococcus saccharolyticus), and combinations thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210981782.6A CN117618338A (en) | 2022-08-16 | 2022-08-16 | Stable orlistat medicine water solution and preparation method thereof |
PCT/CN2023/112556 WO2024037451A1 (en) | 2022-08-16 | 2023-08-11 | Stable aqueous oritavancin pharmaceutical solution and preparation method for preparing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210981782.6A CN117618338A (en) | 2022-08-16 | 2022-08-16 | Stable orlistat medicine water solution and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117618338A true CN117618338A (en) | 2024-03-01 |
Family
ID=89940763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210981782.6A Pending CN117618338A (en) | 2022-08-16 | 2022-08-16 | Stable orlistat medicine water solution and preparation method thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117618338A (en) |
WO (1) | WO2024037451A1 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018016715A2 (en) * | 2016-02-18 | 2019-02-19 | Melinta Therapeutics, Inc. | oritavancin formulations? |
EA201892413A1 (en) * | 2016-05-09 | 2019-05-31 | Кселлия Фармасьютикалз Апс | STABILIZED GLYOPEPTID ANTIBIOTIC PREPARATIONS |
CN109937033A (en) * | 2016-09-14 | 2019-06-25 | 儿童医学中心公司 | The composition with penetration enhancers for drug delivery |
EP4014965A1 (en) * | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
-
2022
- 2022-08-16 CN CN202210981782.6A patent/CN117618338A/en active Pending
-
2023
- 2023-08-11 WO PCT/CN2023/112556 patent/WO2024037451A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024037451A1 (en) | 2024-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6393390B2 (en) | Buffer solution having selective bactericidal activity against gram-negative bacteria and method of using the same | |
US9327028B2 (en) | Acetylcysteine compositions and methods of use thereof | |
JP6945452B2 (en) | How to treat bacterial infections | |
EP2307056B1 (en) | Stabilized aqueous formulation containing paracetamol | |
US6635270B2 (en) | NMDA receptor agonist pharmaceutical compositions | |
NZ566100A (en) | Acetylcysteine composition and uses therefor | |
WO2013144814A1 (en) | Stable ready-to-use pharmaceutical composition of pemetrexed | |
CN117618338A (en) | Stable orlistat medicine water solution and preparation method thereof | |
US20090275660A1 (en) | Stable parenteral formulations of tigecycline | |
EP1863481A1 (en) | Methods for administering ixabepilone | |
US20170239323A1 (en) | Oritavancin formulations | |
CA2656630A1 (en) | Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoic acid | |
JP7436206B2 (en) | How to treat bacterial infections | |
Shields et al. | Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration | |
CN114642633A (en) | Vigabatrin preparation liquid composition | |
US20220016054A1 (en) | Epinephrine parenteral formulations | |
CN113197848B (en) | Meta-hydroxylamine bitartrate pharmaceutical composition and preparation method thereof | |
WO2021198995A1 (en) | Stable aqueous parenteral solutions of desglymidodrine | |
WO2024009319A1 (en) | Liquid injectable compositions of trilaciclib | |
KR20230167077A (en) | Ceftibuten administration regimen | |
US20220362157A1 (en) | New hydrocortisone hemisuccinate lyophilizate | |
US20240139282A1 (en) | Liquid dalbavancin compositions | |
NZ795891A (en) | Methods of treating bacterial infections | |
CN112007031A (en) | Ophthalmic preparation | |
GB2209938A (en) | Stabilised neomycin solutions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |